Navigation Links
Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)

BASINGSTOKE, England and PHILADELPHIA, Pennysylvania, March 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP)(NASDAQ: SHPGY), the global specialty biopharmaceutical company, notes that Renovo Group plc, (LSE: RNVO) ("Renovo") has today announced the results of Renovo's latest Phase 2 studies of JUVISTA(R) (human recombinant TGFbeta3) in scar revision surgery (RN1001-319-1009) and in breast augmentation (RN1001-319-1010).

Renovo’s press release can be found on

The two trials announced by Renovo are part of a broad global Phase 2 clinical program to assess the safety, efficacy, dose and dose frequency of JUVISTA in a variety of surgical procedures.

Shire is at present assessing these latest results with all other results produced to date and plans to discuss these with the US Food and Drug Administration (FDA) in 2008 to determine the regulatory path forward in the United States.

Notes to Editors

Financial terms of the agreement with Renovo

Under the terms of the agreement with Renovo, Shire has the exclusive right to commercialize JUVISTA worldwide, with the exception of EU member states.

As previously announced, Shire will bear the cost of clinical trials designed specifically for obtaining US regulatory approval. Renovo will bear the costs of clinical trials designed specifically for obtaining EU regulatory approval. Shire and Renovo will share equally the costs of conducting global clinical trials that are designed for obtaining both US and EU regulatory approvals.

The financial terms of the agreement are geared to the success of the development and commercialization of JUVISTA. Shire has paid Renovo US$75 million cash upfront (expensed as R&D for US GAAP purposes) and made an equity investment in Renovo Group plc of US$50 million (at a subscription price of GBP2 per share, which at the date of the original announcement represented approximately 7% of Renovo's share capital).

On the FDA's acceptance of the filing of the biologics license application for JUVISTA, Shire will pay US$25 million and on FDA approval, between US$50 and US$150 million depending on the characteristics of the approved product labelling. In addition, Shire will pay to Renovo royalties on sales of JUVISTA and milestone payments of up to US$525 million on the achievement of significant sales targets.


Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGFβ3) and GA-GCB (velaglucerase alfa); manufacturing and commercialization including, but not limited to, the launch and establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products including, but not limited to, the impact of those on Shire's ADHD franchise; patents including, but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval including, but not limited to, the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
2. DW Healthcare Partners Announces the Sale of Tandem Labs
3. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
4. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
5. Announces Distribution of Spectra Intelligence Research
6. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
7. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
8. Wyeth Announces Executive Change in Finance Organization
9. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
10. Pharmacopeia Announces Management Team Changes
11. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
Breaking Biology News(10 mins):